세계의 측방유동 어세이 시장 : 제품별, 용도별, 수법별, 샘플 유형별, 최종 사용자별, 지역별, 예측(-2030년)

The lateral flow assays market is estimated to grow from USD 8.51 billion in 2025 to USD 12.52 billion by 2030 at a CAGR of 8.0%, during the forecast period.

This is due to the high prevalence of infectious diseases worldwide and the subsequent need for testing, rapid growth in the geriatric population, the rising use of home-based lateral flow assay devices, and the growing demand for POC testing, which are the major factors driving the growth of this market. However, inconsistent accuracy compared to other methods and the reluctance of doctors and patients to shift from traditional diagnostics restrain the growth of the lateral flow assays market.

"The clinical testing segment of the lateral flow assays market, by application, is estimated to hold the largest position during the forecast period."

The clinical testing segment is the largest application segment in the lateral flow assays market. Based on applications, the lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing. The clinical testing segment accounted for the largest share of the lateral flow assays market in 2024. This trend is projected to continue during the study period. The large share of this application segment can be attributed to the rising prevalence of chronic diseases and infectious diseases worldwide, the growing geriatric population, increasing patient awareness about rapid test options, the growing pressure to reduce healthcare costs, and the increasing demand for patient-centric care.

"The hospitals & clinics segment accounted for the largest market share in the lateral flow assays market."

Based on end users, the LFA market is segmented into hospitals & clinics, diagnostic laboratories, home care settings, pharmaceutical & biotechnology companies, and others. The hospitals and clinics segment accounted for the largest market share in 2024. Technological advancements, increasing adoption of point-of-care testing, and the growing inclination toward fast and early diagnosis are driving the growth of the hospitals & clinics segment.

"North America segment of the lateral flow assays market, by region, is estimated to account for the largest share during the forecast period."

The global lateral flow assays market is segmented into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC Countries. North America holds the leading position in this market, driven by advanced healthcare infrastructure, significant healthcare expenditure, and the strong presence of key manufacturers. The increasing aging population, rising prevalence of infectious and chronic diseases, and strong demand for home-use and self-test kits further support market growth in North America. This regional segment is expected to maintain its dominant position throughout the forecast period.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1: 40%, Tier 2: 30%, and Tier 3: 35%
• By Designation: C Level: 27%, Director Level: 18%, and Others: 55%
• By Region: North America: 50%, Europe: 20%, Asia Pacific: 20%, Latin America: 7%, and Middle East & Africa: 3%

Note 1: Companies are classified into tiers based on their total revenue. As of 2024, Tier 1 = Greater than USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = Less than USD 1.00 billion.

Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.

Note 3: Other designations include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.

The major players operating in the lateral flow assays market are Abbott Laboratories (US), F. Hoffman-La Roche Ltd. (Switzerland), Danaher Corporation (US), Becton, Dickinson and Company (US), QuidelOrtho Corporation (US), Siemens AG (Germany), bioMerieux SA (France), Thermo Fisher Scientific, Inc. (US), Revvity, Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), Merck KGaA (Germany), Surmodics, Inc. (US), and OraSure Technologies Inc. (US).

Research Coverage

This report studies the lateral flow assays market based on product, application, technique, sample type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends. It forecasts the revenue of the market segments with respect to six major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the strategies mentioned below to strengthen their market presence.

This report provides insights on the following points:

• Analysis of key drivers (High prevalence of infectious diseases, Rising geriatric population, Growing use of home-based lateral flow assay devices, and Growing demand for POC testing), restraints (Inconsistent results of lateral flow assay tests), opportunities (Evolving applications of lateral flow assays and Rising demand for lateral flow assays in food & beverage industry), challenges (Limited reimbursements for lateral flow assay products and Difficulties in procuring quality raw materials to develop tests).
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the lateral flow assays market
• Product Development/Innovation: Detailed insights into the upcoming trends, R&D activities, and product launches in the lateral flow assays market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the lateral flow assays market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS & EXCLUSIONS
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Key data from primary sources
    • 2.1.2.4 Breakdown of primary interviews
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
    • 2.2.1.1 Approach 1: Company revenue estimation approach
    • 2.2.1.2 Approach 2: Presentations of companies and primary interviews
    • 2.2.1.3 Approach 3: Primary interviews
    • 2.2.1.4 Approach 4: Growth Forecast
    • 2.2.1.5 CAGR projections
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 MARKET BREAKDOWN & DATA TRIANGULATION
• 2.4 RESEARCH ASSUMPTIONS
  • 2.4.1 STUDY-RELATED ASSUMPTIONS
  • 2.4.2 GROWTH RATE ASSUMPTIONS
• 2.5 RISK ASSESSMENT
• 2.6 RESEARCH LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 LATERAL FLOW ASSAYS MARKET OVERVIEW
• 4.2 ASIA PACIFIC: LATERAL FLOW ASSAYS MARKET, BY APPLICATION AND COUNTRY
• 4.3 LATERAL FLOW ASSAYS MARKET, BY COUNTRY
• 4.4 LATERAL FLOW ASSAYS MARKET: REGIONAL MIX
• 4.5 LATERAL FLOW ASSAYS MARKET: EMERGING ECONOMIES VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 High prevalence of infectious diseases
    • 5.2.1.2 Rise in geriatric population
    • 5.2.1.3 Growing use of home-based lateral flow assay devices
    • 5.2.1.4 Growth in demand for POC testing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Inconsistent results of lateral flow assays
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Evolving applications of lateral flow assays
    • 5.2.3.2 Rise in demand for lateral flow assays in food & beverage industry
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Limited reimbursements for lateral flow assay products
    • 5.2.4.2 Difficulties in procuring quality raw materials to develop tests
• 5.3 TECHNOLOGY ANALYSIS
  • 5.3.1 KEY TECHNOLOGIES
    • 5.3.1.1 Immunochromatography
  • 5.3.2 COMPLEMENTARY TECHNOLOGIES
    • 5.3.2.1 Lyophilization (Freeze-drying) Technologies
  • 5.3.3 ADJACENT TECHNOLOGIES
    • 5.3.3.1 ELISA (ENZYME-LINKED IMMUNOSORBENT ASSAYS)
• 5.4 PORTER'S FIVE FORCES ANALYSIS
  • 5.4.1 BARGAINING POWER OF SUPPLIERS
  • 5.4.2 BARGAINING POWER OF BUYERS
  • 5.4.3 THREAT OF NEW ENTRANTS
  • 5.4.4 THREAT OF SUBSTITUTES
  • 5.4.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.5 REGULATORY LANDSCAPE
  • 5.5.1 REGULATORY ANALYSIS
    • 5.5.1.1 North America
    • 5.5.1.2 Europe
    • 5.5.1.3 Asia Pacific
      • 5.5.1.3.1 India
      • 5.5.1.3.2 China
      • 5.5.1.3.3 Japan
  • 5.5.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.5.2.1 North America
    • 5.5.2.2 Europe
    • 5.5.2.3 Asia Pacific
    • 5.5.2.4 Latin America
    • 5.5.2.5 Rest of the world
• 5.6 PATENT ANALYSIS
• 5.7 TRADE ANALYSIS
  • 5.7.1 IMPORT DATA (HS CODE 382200)
  • 5.7.2 EXPORT DATA (HS CODE 382200)
• 5.8 PRICING ANALYSIS
  • 5.8.1 INDICATIVE AVERAGE SELLING PRICE TREND, BY REGION
• 5.9 KEY CONFERENCES AND EVENTS
• 5.10 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.10.2 BUYING CRITERIA
• 5.11 UNMET NEEDS/END-USER EXPECTATIONS IN LATERAL FLOW ASSAYS MARKET
• 5.12 VALUE CHAIN ANALYSIS
• 5.13 SUPPLY CHAIN ANALYSIS
• 5.14 IMPACT OF AI ON LATERAL FLOW ASSAYS MARKET
  • 5.14.1 INTRODUCTION
  • 5.14.2 MARKET POTENTIAL OF AI IN LATERAL FLOW ASSAYS MARKET
  • 5.14.3 AI USE CASES
  • 5.14.4 KEY COMPANIES IMPLEMENTING AI
  • 5.14.5 FUTURE OF AI IN LATERAL FLOW ASSAYS MARKET
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 QUIDEL LAUNCHED NEW TEST WITH BROADER DETECTION WINDOW
  • 5.16.2 ABINGTON OFFERED HIGH-SENSITIVITY TESTS FOR GREATER QUALITY
  • 5.16.3 SIEMENS OFFERS HIGH-SENSITIVITY TROPONIN I ASSAY TO RAPIDLY DETECT ACUTE MYOCARDIAL INFARCTION
• 5.17 ADJACENT MARKETS FOR LATERAL FLOW ASSAYS MARKET
• 5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.19 INVESTMENT AND FUNDING SCENARIO
• 5.20 IMPACT OF US TARIFF REGULATION ON LATERAL FLOW ASSAYS MARKET
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 KEY IMPACTS ON COUNTRY/REGION
    • 5.20.4.1 North America
    • 5.20.4.2 Europe
    • 5.20.4.3 Asia Pacific
  • 5.20.5 IMPACT ON END-USE INDUSTRIES
    • 5.20.5.1 Hospitals and Clinics

6 LATERAL FLOW ASSAYS MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 KITS & REAGENTS
  • 6.2.1 RISE IN DEMAND FOR POC TESTING TO DRIVE MARKET
• 6.3 READERS
  • 6.3.1 DIGITAL/HANDHELD READERS
    • 6.3.1.1 Technological evolution and demand for accuracy to drive adoption
  • 6.3.2 BENCHTOP READERS
    • 6.3.2.1 Lower diagnosis cost per patient to drive segment

7 LATERAL FLOW ASSAYS MARKET, BY APPLICATION

• 7.1 INTRODUCTION
• 7.2 CLINICAL TESTING
  • 7.2.1 INFECTIOUS DISEASE TESTING
    • 7.2.1.1 Mosquito-borne diseases
      • 7.2.1.1.1 Increase in incidence of dengue and introduction of more reliable test kits to drive market
    • 7.2.1.2 Influenza
      • 7.2.1.2.1 Rise in prevalence of influenza globally to boost market growth, despite lower sensitivity of lateral flow assays
    • 7.2.1.3 Sexually transmitted infections
      • 7.2.1.3.1 HIV
        • 7.2.1.3.1.1 Growing need for early detection and awareness of HIV POC testing to drive market
      • 7.2.1.3.2 HPV
        • 7.2.1.3.2.1 Rapid HPV diagnostics and real-time PCR, covering broad range of genotypes, coupled with higher incidence of cervical cancer to drive segment
      • 7.2.1.3.3 Chlamydia
        • 7.2.1.3.3.1 Greater viability of advanced techniques to drive market
      • 7.2.1.3.4 Gonorrhea
        • 7.2.1.3.4.1 Rising incidence of gonorrhea and antimicrobial resistance to augment growth
      • 7.2.1.3.5 Syphilis
        • 7.2.1.3.5.1 Need for early and accessible diagnosis to fuel growth
      • 7.2.1.3.6 Other sexually transmitted infections
    • 7.2.1.4 Hepatitis
      • 7.2.1.4.1 Nucleic acid hybridization-based LFAs to show strong potential in hepatitis testing
    • 7.2.1.5 Tuberculosis
      • 7.2.1.5.1 Rise in prevalence and growing focus on early diagnosis and treatment to propel market
    • 7.2.1.6 Other infectious diseases
  • 7.2.2 CARDIAC MARKER TESTING
    • 7.2.2.1 Troponin I & T
      • 7.2.2.1.1 Introduction of high-sensitivity troponin assays to support market growth
    • 7.2.2.2 CK-MB
      • 7.2.2.2.1 Growing applications of lateral flow tests in acute myocardial injuries to drive market
    • 7.2.2.3 BNP & NT-proBNP
      • 7.2.2.3.1 Increase in demand for cardiac biomarker tests to detect heart stress and damage to support growth
    • 7.2.2.4 Myoglobin
      • 7.2.2.4.1 Availability of new high-sensitivity cardiac troponin assays to restrict market growth
    • 7.2.2.5 D-Dimer
      • 7.2.2.5.1 Rising incidence of CVDs to drive market for D-dimer tests
    • 7.2.2.6 Other cardiac marker testing
  • 7.2.3 PREGNANCY & FERTILITY TESTING
    • 7.2.3.1 Pregnancy testing
      • 7.2.3.1.1 Pregnancy testing to hold larger market share but register slower growth
    • 7.2.3.2 Fertility testing
      • 7.2.3.2.1 Rise in infertility rates to drive demand for POC fertility testing kits
  • 7.2.4 CHOLESTEROL/LIPID TESTING
    • 7.2.4.1 Lifestyle changes, cardiovascular disorder incidence to drive segment
  • 7.2.5 DRUGS-OF-ABUSE TESTING
    • 7.2.5.1 Technological advancements and rising focus on workplace drug testing to drive market
  • 7.2.6 OTHER CLINICAL TESTS
• 7.3 VETERINARY DIAGNOSTICS
  • 7.3.1 INFECTIOUS DISEASE OUTBREAKS AND TESTS AVAILABLE FOR DIFFERENT SPECIES TO DRIVE FRAGMENTED MARKET
• 7.4 FOOD SAFETY & ENVIRONMENT TESTING
  • 7.4.1 HIGH SENSITIVITY AND EASE OF USE TO BOOST DEMAND FOR ASSAYS TO CLEAR FOODS FOR MARKET AVAILABILITY
• 7.5 DRUG DEVELOPMENT & QUALITY TESTING
  • 7.5.1 GREATER FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO SUPPORT MARKET GROWTH

8 LATERAL FLOW ASSAYS MARKET, BY TECHNIQUE

• 8.1 INTRODUCTION
• 8.2 SANDWICH ASSAYS
  • 8.2.1 WIDE RANGE OF APPLICATIONS IN CLINICAL TESTING TO SUPPORT MARKET GROWTH
• 8.3 COMPETITIVE ASSAYS
  • 8.3.1 REDUCED SELECTIVITY AND SENSITIVITY COMPARED TO SANDWICH ASSAYS TO HAMPER GROWTH
• 8.4 MULTIPLEX DETECTION ASSAYS
  • 8.4.1 HIGHER ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO FUEL MARKET

9 LATERAL FLOW ASSAYS MARKET, BY SAMPLE TYPE

• 9.1 INTRODUCTION
• 9.2 BLOOD SAMPLES
  • 9.2.1 SIGNIFICANT USE OF BLOOD SAMPLES FOR INFECTIOUS DISEASE TESTING TO DRIVE MARKET
• 9.3 URINE SAMPLES
  • 9.3.1 GROWING USE OF URINE SAMPLES FOR PREGNANCY AND DRUGS-OF-ABUSE TESTING TO DRIVE MARKET
• 9.4 SALIVA SAMPLES
  • 9.4.1 EASY AND LOW-COST COLLECTION, TRANSPORT, AND ANALYSIS OF SALIVA SAMPLES TO SUPPORT ADOPTION
• 9.5 OTHER SAMPLES

10 LATERAL FLOW ASSAYS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS & CLINICS
  • 10.2.1 HIGH DEMAND FOR DIAGNOSTICS ACROSS LARGE POOLS OF PATIENTS IN HOSPITALS TO DRIVE MARKET
• 10.3 HOME CARE SETTINGS
  • 10.3.1 GROWING ACCEPTANCE OF REMOTE MONITORING TO PROPEL MARKET
• 10.4 DIAGNOSTIC LABORATORIES
  • 10.4.1 LABORATORY TESTING LARGELY PREFERRED OVER PROFESSIONAL SETTINGS FOR URINE AND BLOOD TESTING
• 10.5 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.5.1 INCREASE IN FOCUS ON PRODUCT SAFETY TO DRIVE ADOPTION OF LATERAL FLOW ASSAYS
• 10.6 OTHER END USERS

11 LATERAL FLOW ASSAYS MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 Large patient base to drive market growth
  • 11.2.3 CANADA
    • 11.2.3.1 Availability of research funding and implementation of favorable government initiatives to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 Well-developed healthcare system and rise in geriatric population to fuel growth
  • 11.3.3 UK
    • 11.3.3.1 Growth in incidence of chronic conditions to propel market growth
  • 11.3.4 FRANCE
    • 11.3.4.1 High prevalence of age-related chronic diseases and infectious diseases to drive market
  • 11.3.5 ITALY
    • 11.3.5.1 Growth in initiatives toward decentralization of medical services to support market growth
  • 11.3.6 SPAIN
    • 11.3.6.1 Aging population and strong healthcare infrastructure to drive market
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 Growing elderly population and well-developed healthcare system to drive market
  • 11.4.3 CHINA
    • 11.4.3.1 Modernized healthcare system to drive market
  • 11.4.4 INDIA
    • 11.4.4.1 Growth in healthcare concerns and rise in income levels to propel market growth, despite lack of reimbursement and insurance coverage for lateral flow assay products
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Rise in prevalence of infectious disease and healthcare expenditure to support growth
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Growth in healthcare infrastructure to drive market
  • 11.4.7 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 High private healthcare expenditure and rise in geriatric population to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Increase in demand for advanced medical equipment to drive market
  • 11.5.4 ARGENTINA
    • 11.5.4.1 Availability of health insurance to favor market growth
  • 11.5.5 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
• 11.7 GCC COUNTRIES
  • 11.7.1 RISE IN DEMAND FOR RAPID AND COST-EFFECTIVE DIAGNOSTICS TO DRIVE MARKET

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN LATERAL FLOW ASSAYS MARKET
• 12.3 REVENUE ANALYSIS, 2020-2024
• 12.4 MARKET SHARE ANALYSIS, 2024
• 12.5 COMPANY VALUATION AND FINANCIAL METRICS
• 12.6 BRAND/PRODUCT COMPARISON
• 12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.7.1 STARS
  • 12.7.2 EMERGING LEADERS
  • 12.7.3 PERVASIVE PLAYERS
  • 12.7.4 PARTICIPANTS
  • 12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.7.5.1 Company footprint
    • 12.7.5.2 Regional Footprint
    • 12.7.5.3 Product Footprint
    • 12.7.5.4 Technique Footprint
    • 12.7.5.5 Application Footprint
    • 12.7.5.6 Sample type Footprint
• 12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.8.1 PROGRESSIVE COMPANIES
  • 12.8.2 RESPONSIVE COMPANIES
  • 12.8.3 DYNAMIC COMPANIES
  • 12.8.4 STARTING BLOCKS
  • 12.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.8.5.1 Detailed list of key startup/SME players
    • 12.8.5.2 Competitive benchmarking of key startups/SMEs
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ABBOTT LABORATORIES
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches & approvals
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 F. HOFFMANN-LA ROCHE LTD.
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 MnM view
      • 13.1.2.3.1 Right to win
      • 13.1.2.3.2 Strategic choices
      • 13.1.2.3.3 Weaknesses and competitive threats
  • 13.1.3 DANAHER CORPORATION
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 MnM view
      • 13.1.3.3.1 Right to win
      • 13.1.3.3.2 Strategic choices
      • 13.1.3.3.3 Weaknesses and competitive threats
  • 13.1.4 QUIDELORTHOORTHO CORPORATION
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Deals
  • 13.1.5 SIEMENS AG
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
  • 13.1.6 BECTON, DICKINSON AND COMPANY
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
  • 13.1.7 BIOMERIEUX SA
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Deals
  • 13.1.8 THERMO FISHER SCIENTIFIC INC.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 REVVITY, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 QIAGEN N.V.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 MERCK KGAA
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Expansions
  • 13.1.12 HOLOGIC, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Deals
  • 13.1.13 SURMODICS, INC.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Deals
  • 13.1.14 ORASURE TECHNOLOGIES
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
• 13.2 OTHER PLAYERS
  • 13.2.1 CHEMBIO DIAGNOSTICS INC.
  • 13.2.2 DCN DIAGNOSTICS
  • 13.2.3 POLYSCIENCES INC.
  • 13.2.4 ABINGDON HEALTH
  • 13.2.5 ORANOXIS INC.
  • 13.2.6 AESKU.GROUP GMBH
  • 13.2.7 BIO GROUP MEDICAL SYSTEM S.R.L
  • 13.2.8 PHARMACT GMBH
  • 13.2.9 XIAMEN BIOTIME BIOTECHNOLOGY CO., LTD.
  • 13.2.10 BIOPANDA REAGENTS LTD
  • 13.2.11 ARTRON LABORATORIES INC.

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS